Search

Displaying results 1201 - 1210 of 1777 in total
  1. Drug

    Tamsulosin

    go.drugbank.com/drugs/DB00706
    ApprovedInvestigational

    [A178351] Tamsulosin was first approved by the FDA on April 15, 1997.[L6238]

  2. Drug

    Tetracycline

    go.drugbank.com/drugs/DB00759
    ApprovedInvestigationalVet approvedWithdrawn

    The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.

  3. Drug

    Saquinavir

    go.drugbank.com/drugs/DB01232
    ApprovedInvestigational

    In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared

  4. Drug

    Sunitinib

    go.drugbank.com/drugs/DB01268
    ApprovedInvestigational

    On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).

  5. Drug

    Thymidine

    go.drugbank.com/drugs/DB04485
    ApprovedInvestigational

    biochemical modulator to enhance the efficacy and reduce the toxicity of established anti-metabolite chemotherapeutic agents, such as 5-Fluorouracil (FU), Methotrexate (MTX), and Cytosine arabinoside (ara-C

  6. Drug

    Orforglipron

    go.drugbank.com/drugs/DB18964
    ApprovedInvestigational

    [L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations.

  7. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    On May 18, 2026, baxdrostat was approved by the FDA as a first-in-class aldosterone synthase inhibitor for the treatment of hypertension in combination with other antihypertensive drugs [L56189].

  8. Drug

    Telmisartan

    go.drugbank.com/drugs/DB00966
    ApprovedInvestigational

    Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinit...

    Mixtures: Nra-telmisartan/hctz, Nra-telmisartan/hctzProducts: Nra-telmisartan
  9. Drug

    Pibrentasvir

    go.drugbank.com/drugs/DB13878
    ApprovedInvestigational

    the emergence of amino acid substitutions at known NS5A inhibitor resistance-associated positions in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility and resistance to pibrentasvir [FDA … This fixed-dose combination therapy was FDA-approved in August 2017 to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including

  10. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    the data [A235720] and aducanumab was granted accelerated FDA approval on 7 June 2021. … [A235720] Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing